✦ LIBER ✦

Valganciclovir for the prophylaxis of early cytomegalovirus (CMV) infection after allogeneic stem cell transplantation

✍ Scribed by C. Bachier; P. Shaughnessy; D. Wall; M. Grimley; G. Carrum; C. Freytes; N. Callander; T. Walsh; C.F. LeMaistre

Book ID: 116278223
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 68 KB
Volume: 11
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2004.12.267

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Valganciclovir is effective in the preem

Valganciclovir is effective in the preemptive treatment of cytomegalovirus (CMV) infection after allogeneic stem cell transplant (ASCT)

✍ M.F. Aberle; C. Bachier; F.C. Lemaistre; P.J. Shaughnessy 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 64 KB

The Impact of Pre-Transplant Valganciclo

The Impact of Pre-Transplant Valganciclovir on Early Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplant

✍ K. Wilhelm; A. Gulbis; I. Maewal; R. Cool; J. Ferguson; M. Westmoreland; C. Mart 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 79 KB

Oral valganciclovir as preemptive therap

Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation

✍ A. Busca; P. De Fabritiis; V. Ghisetti; T. Allice; M. Mirabile; G. Gentile; F. L 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

Foscarnet – an alternative for cytomegal

Foscarnet – an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation?

✍ R. Ordemann; R. Naumann; G. Geißler; F. Kroschinsky; M. Bornhäuser; R. Schwerdtf 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 130 KB

Question of using valganciclovir for cyt

Question of using valganciclovir for cytomegalovirus (CMV) infection prophylaxis in post–liver transplant recipients

✍ Ashok Jain; Ravi Mohanka; Mark Orloff; Peter Abt; Charlotte Ryan; Adel Bozorgzad 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

We read the article by Park et al. with great interest. 1 The authors retrospectively studied the efficacy of low-dose oral valganciclovir (n ϭ 49) compared with the standard dose of ganciclovir (n ϭ 60) for the prevention of cytomegalovirus (CMV) disease in adult liver transplant recipients. The au

Evaluation of the nuclisens CMV pp67 ass

Evaluation of the nuclisens CMV pp67 assay for detection of cytomegalovirus infection after allogeneic stem cell transplantation

✍ Hermann Einsele 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 79 KB